Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease

Dalin Li, PhD, Philip Debbas, Susan Cheng, MD, MS, Jonathan Braun, MD, Dermot P.B. McGovern, MD, PhD, Gil Y. Melmed, MD, MS

Contributing authors: Coronavirus Risk Associations and Longitudinal Evaluation-Inflammatory Bowel Disease (CORALE-IBD) Study Group:

Andrea Banty, Edward Feldman, Christina Ha, Susie Lee, Shervin Rabizadeh, Theodore Stein, Theodore Solomon, Gaurav Syal, Stephan Targan, Eric Vasiliauskas, David Ziring, Niru Bonthala, Gregory S. Botwin, Melissa Hampton, Emebet Mengesha, Elizabeth Khanishian, Valeriya Pozdynyakova, Phillip Gu, Angela Mujukian, Shane White, Cindy Zamudio, Daniel Gonzalez, Alyssa Parry, Mary Hanna, Justin Chan

Joe Ebinger, Sandy Joung, Min Wu, Amy Hoang, Timothy Wynter, Nancy Sun

Jane C. Figueiredo, Akil Merchant, Noah Merin, Karen L. Reckamp

Keren Appel

Rashmi Kumar

Brigid Boland

Aline Charabaty

Michael Chiorean

Erica Cohen

Ann Flynn, John Valentine

Adam C. Ehrlich

David Fudman

Arash Horizon, Dmitry Karayev, Benjamin Kretzmann

Jason Hou

Caroline Hwang

Mark Lazarev

Donald Lum, Rebecca Fausel, Swapna Reddy

Ryan McConnell

Mark C. Mattar

Mark Metwally, Arthur Ostrov

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Nimisha Parekh
Laura Raffals
David T. Rubin
Sarah Sheibani
Corey A. Siegel
Douglas Wolf
Ziad Younes
Oriana Damas

Affiliations:

1Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
2Smidt Heart Institute, Department of Medicine, Cedars-Sinai, Los Angeles, CA
3Samual Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles, CA
4Children’s Hospital, Orange County, CA
5Banner University Medical Center, Phoenix, AZ
6University of California, San Diego, CA
7Sibley Memorial Hospital, Johns Hopkins, Washington, DC
8Swedish Medical Center, Seattle, WA
9Capital Digestive Care, Chevy Chase, MD
10University of Utah, Salt Lake City, UT
11Temple University, Philadelphia, PA
12UT Southwestern, Dallas, TX
13Center for Rheumatology, Los Angeles, CA
14Baylor College of Medicine, Houston, TX
15Hoag Hospital, Newport Beach, CA
16Johns Hopkins Hospital, Baltimore, MD
17The Oregon Clinic, Portland, OR
18Sutter Health, Palo Alto, CA
19Medstar-Georgetown, Washington, DC
Acknowledgements: We thank all patient participants of the CORALE-IBD Vaccine study.

Corresponding Author:
Gil Y. Melmed, MD, MS, FACP, AGAF
Inflammatory Bowel and Immunobiology Research Institute
Karsh Division of Digestive and Liver Diseases
Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA 90048
310-423-4100
gil.melmed@cshs.org

Funding:
This study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported by the Cedars-Sinai Precision Health Initiative, and the Erika J. Glazer Family Foundation.

Potential Conflicts of Interest:
GYM has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-initiated study. JB has received research funding from Janssen. JCP, JLS, and ECF work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were
collected for this study. DPBM: Bridge Biotherapeutics, Gilead, Palatin, Pfizer, Promteheus Biosciences, Prometheus Laboratories, Takeda. MC: Abbvie, Arena, Bristol-Meyers Squibb, Janssen, Medtronic, Pfizer, and Takeda. EC: Abbvie and Pfizer. DF: Pfizer. CH: Abbvie, Janssen, and Pfizer. DL: Abbvie, Janssen and Takeda. RM: Abbvie, Bristol Myers Squibb, Pfizer, and Prometheus Bioscience. NP: Pfizer. DW: Abbvie, Arena, Bristol Meyers Squibb, Corevitas, Janssen, Lilly, Pfizer, and Takeda. BM: Abbvie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda. SG: Abbvie, Janssen, and Takeda. CH: Abbvie, Bristol Meyers Squibb, Genentech, InbDex Pharmaceuticals, Janssen, Lilly, and Pfizer. GS: research funding for unrelated investigator study from Pfizer. ST: Prometheus Bioscience.

The remaining authors have no competing interests.

**Author Contributions:**

Study concept and design: GM, DL, GB, JB, DM

Acquisition of data: GM, DL, GB, DM

Analysis and interpretation of data: all authors

Drafting of the manuscript: GM

Critical revision of the manuscript for important intellectual content: all authors

Statistical analysis: DL

Obtained funding: GM, JB, DM

Study supervision: GM, JB, DM

**Word Count:** 977 (limit 1000)

**No. References:** 5 (limit 5)
Abstract:

Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population. The symptom profile after a 3rd mRNA vaccine dose in the predominantly immune-compromised IBD population is unknown. We aimed to assess symptomology after a 3rd or booster dose of mRNA vaccination in adults with IBD. We surveyed participants of the Coronavirus Risk Associations and Longitudinal Evaluation in IBD (CORALE-IBD) post-vaccination registry for symptom frequency and severity after a 3rd mRNA vaccine dose in an observational cohort study. In total, 524 participants (70% female, mean age 45 years) reported a third dose of mRNA vaccination through October 11, 2021. Overall, 41% reported symptoms after a third dose, with symptoms generally more frequent and more severe among participants younger than 55 years. The most frequent postvaccination symptoms were injection site pain (39%), fatigue or malaise (34%), and headache (23%). These symptoms were all less frequently reported after dose 3 than after dose 2. Gastrointestinal symptoms were reported by 8.8%, which was slightly more frequent than after dose 2 (7.8%). Those with severe symptoms after dose 2 were more likely to have severe symptoms after dose 3. These findings can reassure the IBD patient and provider communities that the likelihood and distribution of symptoms after a third mRNA vaccine dose are generally similar to those after a second dose, and that the frequency of postvaccination symptoms after dose 3 are generally lower than after dose 2.
Introduction

Vaccine safety concerns are a major contributor to vaccine hesitancy.1 Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population,2, 3 although adverse events after the second dose of a two-dose primary inoculation are more frequent and severe than after the first dose.4 In the general population, the frequency of reactions after a third dose of mRNA vaccination in the general population was similar to the second dose.5 However, the symptom profile after a 3rd mRNA vaccine dose in the predominantly immune-compromised IBD population is unknown. We aimed to assess symptomology after a 3rd or booster dose of mRNA vaccination in adults with IBD.

Methods

Adults with IBD participating in the prospective Coronavirus Risk Associations and Longitudinal Evaluation in IBD (CORALE-IBD) vaccine registry were queried after FDA approval of a 3rd dose of mRNA vaccine for patients receiving immune suppressive therapy. Participants who received a 3rd dose were asked to complete a detailed survey about post-vaccination symptoms 1 week after vaccination. Given that symptoms after the second dose of the primary series were more frequent and severe than after the first dose, we compared the frequency and severity of symptoms after dose 3 relative to those reported after dose 2 (R version 3.5.1). Symptoms were assessed across eleven organ systems, including injection site symptoms (pain, erythema, swelling); fatigue or malaise; headache, dizziness or lightheadedness; fever or chills; rheumatologic (muscle, joint, or nerve) symptoms, gastrointestinal (nausea, vomiting, abdominal pain, diarrhea, or other) symptoms; sleep changes; swollen lymph nodes; skin/nail or facial changes; eye, ear, mouth or throat changes; cough, chest or breathing symptoms, and
memory or mood changes. Symptoms were graded by severity as mild, moderate, or severe impact on activities of daily living, or requiring hospitalization as defined in Baden et al\textsuperscript{3}. The category of “severe+” included those with severe symptoms, as well as those with need for hospitalization. Given the distinct symptom profiles experienced by older people relative to younger vaccine recipients after dose 2, we stratified patients by age less than or \textgeq 50. We also constructed a 3x3 severity table (none-mild, moderate, and severe+) to clarify the frequency of severe symptoms after dose 3 relative to the severity of symptoms experienced after dose 2. The study protocol was approved by the Cedars-Sinai institutional review board. All study participants provided informed consent.

**Results**

The cohort included 524 participants (70% female, mean age 45 years) reporting a third dose of mRNA vaccination through October 11, 2021. A majority had Crohn’s disease (71%) with the remainder having ulcerative colitis or IBD-unclassified, and 89% were receiving biologic therapies. Most participants (58%) received primary vaccination with BNT562b2, and only 3.5% of the overall cohort reported a previous COVID infection at the time of initial vaccination. Overall, 97% of subjects received a third dose with the same mRNA vaccine as in their initial series with the remainder receiving the other mRNA vaccine type. No participants received a third dose with the Ad26.CoV.2 (J&J) vaccine.

Overall, 41% reported symptoms after a third dose, with symptoms generally more frequent and more severe among participants younger than 55 years (Supplemental Table 1). The most frequent postvaccination symptom was injection site pain (39%). Commonly reported systemic symptoms were fatigue or malaise (34%), headache (23%), and muscle, bone and joint symptoms (13%). These symptoms were all less frequently reported after dose 3 than after dose 2 (Figure). Gastrointestinal symptoms were reported by 8.8%, which was slightly more frequent than after dose 2 (7.8%). Among those with postvaccination symptoms, the proportion
with severe+ symptoms after dose 3 was lower than dose 2 for fatigue/malaise, headache, dizziness and lightheadedness, fever or chills, and rheumatologic symptoms, but was slightly higher than dose 2 for gastrointestinal symptoms (Figure).

We evaluated the severity of symptoms after dose 3 by the severity of symptoms after dose 2 (Supplemental Table 2). Overall, the majority (75%) experienced none or mild symptom severity for both doses. Severe+ symptoms were comparable at dose 2 and 3 (17% and 14%, respectively). Of those with severe+ symptoms after dose 2, 34% experienced severe+ symptoms after dose 3 (OR 5.15, p<0.001). In comparison, about 22% experienced severe+ symptoms after dose 3 but did not report severe+ symptoms after dose 2.

Discussion

We demonstrate several key findings with respect to symptoms after a third mRNA vaccine among patients with inflammatory bowel disease. First, post-vaccination symptom frequency and severity are significantly greater among those younger than 55 years. This is similar to findings after a second vaccine dose. Second, symptoms after dose 3 were slightly less frequent and less severe for most organ systems, with the notable exception of gastrointestinal symptoms which were slightly more common and severe after dose 3 relative to dose 2. Third, the frequency of severe+ symptoms were comparable after dose 2 and dose 3. They occurred in one third of those who experienced them after dose 2, and in about 22% of those who did not experience them after dose 2. This suggests that most people with severe+ symptoms after dose 2 do not get severe symptoms after a 3rd dose, but still have a higher likelihood of having severe+ symptoms than those who did not have severe+ symptoms after dose 2. Because about one in five experience severe+ symptoms after dose 3 even without previous severe+ symptoms, patients should consider vaccination at a time when short-lived severe symptoms can be best tolerated and addressed.
Overall, our findings can reassure the IBD patient and provider communities that the likelihood and distribution of symptoms after a third mRNA vaccine dose are generally similar to those after a second dose, and that for most organ systems, fewer people experienced postvaccination symptoms after dose 3 than after dose 2. Further evaluation of postvaccination gastrointestinal symptoms in this population living with chronic gastrointestinal illness is warranted.

References:

1. Dalal RS, McClure E, Marcus J, et al. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021.
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020.
3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2020.
4. Botwin GJ, Li D, Figueiredo J, et al. Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease. medRxiv 2021.
5. Hause AM, Baggs J, Gee J, et al. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1379-1384.

Figure: Severity of Symptoms by System for Dose 3 relative to Dose 2
